Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) insider Jason B. Shandell sold 16,630 shares of the company’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $22.44, for a total value of $373,177.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Shares of NASDAQ:AMPH opened at $21.99 on Friday. Amphastar Pharmaceuticals Inc has a 1 year low of $14.40 and a 1 year high of $22.74. The company has a market cap of $1.00 billion, a PE ratio of 108.60 and a beta of 1.42. The company has a debt-to-equity ratio of 0.10, a quick ratio of 1.34 and a current ratio of 2.02.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last announced its earnings results on Thursday, November 8th. The company reported $0.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.11 by $0.01. Amphastar Pharmaceuticals had a positive return on equity of 2.80% and a negative net margin of 2.33%. The firm had revenue of $75.54 million for the quarter, compared to analyst estimates of $76.84 million. During the same quarter last year, the firm posted $0.07 EPS. The business’s revenue was up 30.5% on a year-over-year basis. Sell-side analysts expect that Amphastar Pharmaceuticals Inc will post -0.06 EPS for the current fiscal year.

Large investors have recently made changes to their positions in the company. Piedmont Investment Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $128,000. SG Americas Securities LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $161,000. Nisa Investment Advisors LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $221,000. Paloma Partners Management Co purchased a new position in shares of Amphastar Pharmaceuticals during the 3rd quarter valued at approximately $223,000. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Amphastar Pharmaceuticals during the 2nd quarter valued at approximately $295,000. Hedge funds and other institutional investors own 44.74% of the company’s stock.

Several equities research analysts have commented on AMPH shares. Needham & Company LLC set a $25.00 price objective on Amphastar Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, November 9th. Wells Fargo & Co restated a “buy” rating on shares of Amphastar Pharmaceuticals in a research report on Friday, November 9th. Jefferies Financial Group restated a “buy” rating and issued a $26.00 price objective on shares of Amphastar Pharmaceuticals in a research report on Wednesday, November 14th. BidaskClub lowered Amphastar Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, September 13th. Finally, ValuEngine upgraded Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, August 17th. One research analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and an average target price of $23.60.

ILLEGAL ACTIVITY WARNING: This piece of content was originally reported by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was stolen and republished in violation of international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.watchlistnews.com/insider-selling-amphastar-pharmaceuticals-inc-amph-insider-sells-16630-shares-of-stock/2669656.html.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States and internationally. It operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredients.

Further Reading: What is a Candlestick Chart?

Insider Buying and Selling by Quarter for Amphastar Pharmaceuticals (NASDAQ:AMPH)

Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.